In patients undergoing mastectomy, T.Gabapentin is given to reduce the occurance of post-mastectomy chronic pain

Effect of Gabapentin in reducing the incidence of Post-mastectomy pain syndrome in patients undergoing mastectomy-A pragmatic randomized controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/06/111880

Enrollment

Registered

2026-06-04

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site Health Condition 2: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Gabapentin: T. Gabapentin 300mg orally once daily at bedtime is given to patients undergoing mastectomy one day before surgery and continued upto fourth postoperative day. All patients

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients undergoing unilateral MRM or breast conservative surgery with axillary lymph node dissection. ASA 1-3

Exclusion criteria

Exclusion criteria: Known hypersensitivity to Gabapentin. Current or recent use of gabapentinoid drugs

Design outcomes

Primary

Measure	Time frame
To evaluate effectiveness of Gabapentin in reducing the incidence of post-mastectomy pain syndromeTimepoint: 3 months after surgery	—

Secondary

Measure	Time frame
Severity of post-mastectomy neuropathic pain using VAS score. Quality of life using EQ-5D-5L scaleTimepoint: 3 months after surgery	—

Countries

India

Contacts

Public ContactDr Ananya S Aringoth

Jawaharlal Institute of Postgraduate Medical Education and Research

dr.lenin@gmail.com9487981140

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026